← Back to Search

Polo-like kinase 1 inhibitor

CYC140 for Acute Lymphoblastic Leukemia

Phase 1

Waitlist Available

Led By Gautam Borthakur, MD

Research Sponsored by Cyclacel Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up first dose of cyc140 to 4 weeks after the last dose of cyc140

Awards & highlights

Study Summary

This trial is testing a new drug, CYC140, to see if it can help people with advanced leukemias or myelodysplastic syndromes.

Eligible Conditions

Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ first dose of cyc140 to 4 weeks after the last dose of cyc140

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~first dose of cyc140 to 4 weeks after the last dose of cyc140

This trial's timeline: 3 weeks for screening, Varies for treatment, and first dose of cyc140 to 4 weeks after the last dose of cyc140 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Patients who experience dose -limiting toxicity (DLT)

Secondary outcome measures

Pharmacokinetic measurement - area under the curve (AUC)

Other outcome measures

Anti-tumor activity

Trial Design

1Treatment groups

Experimental Treatment

Group I: CYC140 single agentExperimental Treatment1 Intervention

CYC140 will be administered as a single agent on Day 1 and Day 8 of each 3 week cycle

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterOTHER

2,966 Previous Clinical Trials

1,804,731 Total Patients Enrolled

Cyclacel Pharmaceuticals, Inc.Lead Sponsor

19 Previous Clinical Trials

2,429 Total Patients Enrolled

Gautam Borthakur, MDPrincipal InvestigatorM.D. Anderson Cancer Center

6 Previous Clinical Trials

179 Total Patients Enrolled

Media Library

CYC140 (Polo-like kinase 1 inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03884829 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA approved CYC140 for therapeutic purposes?

"CYC140 has only been tested in a few trials, so there is limited evidence to support its safety and efficacy. Therefore, our team at Power gave it an assessment score of 1."

Answered by AI

What is the upper limit of participants enrolled in this clinical trial?

"Correct. Clinicaltrials.gov hosts the details of this study, which was initially advertised on March 25th 2019 and has been modified most recently on April 22nd 2022. This experiment is searching for 50 individuals at a single medical facility."

Answered by AI

Are there available positions for participants in this medical research endeavor?

"Affirmative. According to clinicaltrials.gov, this research project is recruiting participants; it was initially posted on March 25th 2019 and recently modified on April 22nd 2022. The team needs 50 individuals from one medical centre for the trial."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

2019. "A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03884829.